82
Participants
Start Date
November 12, 2020
Primary Completion Date
May 9, 2024
Study Completion Date
December 31, 2025
brentuximab vedotin
1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
cyclophosphamide
750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
doxorubicin
50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
prednisone
100 mg daily administered orally on Days 1-5 of each cycle
Memorial Sloan Kettering Cancer Center David H. Koch Center for Cancer Care, New York
Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS Candiolo - Oncologia Medica, Candiolo
Memorial Sloan Kettering Cancer Center, New York
IRCCS Ospedale Policlinico San Martino, Genova
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan
VCU Health-Adult Outpatient Pavilion(AOP)Investigational Drug Services(Active as of 5/3/2022), Richmond
VCU Massey Cancer Center-Radiation Oncology, Richmond
VCU Medical Center -InPatient, Richmond
VCU Medical Center Critical Care Hospital, Richmond
Virginia Commonwealth University, Richmond
VCU at Stony Point, Richmond
Massey Cancer Center Clinical & Translational Research Lab, Richmond
Virginia Oncology Associates, Chesapeake
Virginia Oncology Associates, Virginia Beach
Virginia Oncology Associates, Norfolk
Virginia Oncology Associates, Newport News
Virginia Oncology Associates, Hampton
Fondazione Irccs San Matteo, Pavia
IEC Trials, Hospital La Milagrosa., Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario De La Paz, Madrid
Höpital Haut Levéque - CHU Bordeaux Service d'hématologie clinique et thérapie cellulaire, Pessac
University of Alabama at Birmingham, Birmingham
University of Alabama at Birmingham, Birmingham
Hospital Clinico Universitario de Salamanca, Salamanca
Azienda Ospedaliera Universitaria Integrata Verona Policlinico G.B. Rossi, Verona
CHU Grenoble Alpes, Tranche
Azienda Ospedaliero Universitaria di Bologna - IRCCS, Bologna
Cleveland Clinic taussig Cancer Center Investigational Pharmacy, Cleveland
Cleveland Clinic Taussig Cancer Center, Cleveland
Cleveland Clinic, The, Cleveland
Oncology_Hematology Care Clincal Trials,LLC, Fairfield
Oncology_Hematology Care Clincal Trials,LLC, Cincinnati
Oncology_Hematology Care Clincal Trials,LLC, Cincinnati
Oncology_Hematology Care Clincal Trials,LLC, Cincinnati
Oncology_Hematology Care Clincal Trials,LLC, Cincinnati
Hopital Emile Muller, Mulhouse
Tulane Cancer Center, New Orleans
Tulane Medical Center, New Orleans
US Oncology Investigational Products Center (IPC), Irving
US Oncology Investigational Products Center(IPC), Irving
US Oncology lnvestigational Products Center (IPC), Irving
Texas Oncology-Northeast Texas, Paris
Texas Oncology-Northeast Texas, Longview
Texas Oncology-Northeast Texas, Tyler
Texas Oncology-Northeast Texas, Palestine
The University of Texas MD Anderson Cancer Center, Houston
Texas Oncology-Austin Midtown, Austin
Texas Oncology-Austin Central, Austin
Rocky Mountain Cancer centers, LLP, Aurora
Rocky Mountain Cancer centers, LLP, Littleton
Rocky Mountain Cancer centers, LLP, Lone Tree
Rocky Mountain Cancer centers, LLP, Denver
Rocky Mountain Cancer centers, LLP, Denver
Rocky Mountain Cancer centers, LLP, Lakewood
Rocky Mountain Cancer centers, LLP, Thornton
Rocky Mountain Cancer centers, LLP, Boulder
Rocky Mountain Cancer centers, LLP, Longmont
Rocky Mountain Cancer centers, LLP, Colorado Springs
Rocky Mountain Cancer centers, LLP, Pueblo
Stanford Cancer Center, Stanford
Stanford Hospital and Clinics, Investigational Drug Services, Stanford
Cetir Centre Medic, Barcelona
Hospital Duran I Reynals - Institut Catala d'Oncologia, Barcelona
Oxford University Hospitals, Headington
UCLH Hospitals, London
Hammersmith Hospital, London
MACMILLIAN Cancer Centre, London
The Christie NHS Foundation Trust, Manchester
Seagen, a wholly owned subsidiary of Pfizer
INDUSTRY